NCT01487369已完成不适用
Special Survey of Production of Insulin Aspart (IAsp) Specific Antibody
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 204
- 主要终点
- Antibody titre findings
研究概览
简要总结
This study is conducted in Japan. The aim of this study is to collect data of production of insulin aspart specific antibody under normal clinical practice conditions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diabetes requiring insulin therapy
排除标准
- •Patients who had a treatment history of NovoRapid® (insulin aspart)
研究组 & 干预措施
Insulin Aspart
干预措施: insulin aspart (Drug)
结局指标
主要结局
Antibody titre findings
次要结局
- Hypoglycemic events
- HbA1c (glycosylated haemoglobin)
- Adverse events
研究者
相似试验
已完成
1 期
Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy JapaneseHealthyDiabetesNCT01620450Novo Nordisk A/S34
未知
Unknown
Administration study for insulin to healthy Japanese adult malesJPRN-jRCT1080221929Mitsubishi chemical Medience Corporation18
已完成
不适用
Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With InhibitorsCongenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With InhibitorsNCT01586936Novo Nordisk A/S9
已完成
3 期
Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring DiabetesDiabetesDiabetes Mellitus, Type 1NCT00604344Novo Nordisk A/S401
已完成
不适用
Special Survey for Type 1 or Type 2 Diabetic PatientsDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT01487408Novo Nordisk A/S1,463